12th Feb 2014 12:59
LONDON (Alliance News) - The Biotech Growth Trust PLC Wednesday said its net asset value rise beat that of its benchmark in the final three months of 2013 as its holdings in Fluidigm and Incyte paid off, but has since lost a bit of ground. Net asset value rose by 8.2% in the three months to Read More
